JG
TGTX icon

Joel Greenblatt’s TG Therapeutics TGTX Stock Holding History

Joel Greenblatt’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Sell
44,905
-266
-0.6% -$10.9K 0.01% 1096
2026
Q1 		$1.5M Sell
45,171
-10
-0% -$298 ﹤0.01% 1192
2025
Q4 		$1.35M Sell
45,181
-151
-0.3% -$4.93K ﹤0.01% 1163
2025
Q3 		$1.64M Hold
45,332
– – 0.01% 1061
2025
Q2 		$1.63M Sell
45,332
-1,403
-3% -$52.2K 0.01% 994
2025
Q1 		$1.84M Sell
46,735
-4,214
-8% -$142K 0.02% 827
2024
Q4 		$1.53M Sell
50,949
-64,333
-56% -$1.85M 0.01% 782
2024
Q3 		$2.7M Buy
115,282
+41,975
+57% +$917K 0.03% 652
2024
Q2 		$1.3M Buy
73,307
+1,731
+2% +$27.6K 0.02% 808
2024
Q1 		$1.09M Sell
71,576
-24,674
-26% -$393K 0.02% 821
2023
Q4 		$1.64M Buy
96,250
+24,827
+35% +$289K 0.03% 670
2023
Q3 		$597K Sell
71,423
-59,271
-45% -$826K 0.01% 927
2023
Q2 		$3.25M Buy
130,694
+9,807
+8% +$253K 0.07% 393
2023
Q1 		$1.82M Sell
120,887
-5,555
-4% -$84.4K 0.04% 547
2022
Q4 		$1.5M Buy
+126,442
New +$918K 0.04% 531
2021
Q2 		– Sell
-10,756
Closed -$518K – 1101
2021
Q1 		$518K Sell
10,756
-22,960
-68% -$1.1M 0.02% 674
2020
Q4 		$1.75M Buy
33,716
+16
+0% +$541 0.06% 385
2020
Q3 		$902K Sell
33,700
-11,088
-25% -$255K 0.03% 565
2020
Q2 		$872K Buy
+44,788
New +$721K 0.03% 591
2019
Q4 		– Sell
-11,105
Closed -$62K – 1211
2019
Q3 		$62K Buy
+11,105
New +$77.4K ﹤0.01% 1061

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Joel Greenblatt's TGTX Position: Q2 2026 in Review

Joel Greenblatt reduced its TG Therapeutics (TGTX) stake by 0.59% in Q2 2026, selling an estimated $10.9K and leaving 44,905 shares worth $2.47M. The position accounts for 0.01% of the portfolio, ranked #1096.

Joel Greenblatt first reported a position in TGTX in Q3 2019 and has held it in 20 quarters since. The position peaked at $3.25M in Q2 2023. 426 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Joel Greenblatt held 44,905 shares of TG Therapeutics worth $2.47M as of Q2 2026.
  • Joel Greenblatt sold 266 TG Therapeutics shares in Q2 2026, an estimated $10.9K.
  • TG Therapeutics made up 0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1096 holding.
  • Joel Greenblatt first reported a position in TG Therapeutics in Q3 2019 and has held it in 20 quarters since.
  • Joel Greenblatt's TG Therapeutics position peaked at $3.25M in Q2 2023.
  • 426 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.